Yayınlanmış 1 Ocak 2022
| Sürüm v1
Dergi makalesi
Açık
Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application
Oluşturanlar
- Erdogan, Ebru1
- Yalcin, Koray
- Hemsinlioglu, Cansu2
- Sezgin, Aslihan1
- Seyis, Utku2
- Kancagi, Derya Dilek2
- Tastan, Cihan
- Yurtsever, Bulut2
- Turan, Raife Dilek2
- Cakirsoy, Didem2
- Abanuz, Selen2
- Karakus, Gozde Sir2
- Elek, Muhammer2
- Bekoz, Huseyin Saffet3
- Gemici, Ali Ihsan3
- Sargin, Deniz
- Arat, Mutlu4
- Ferhanoglu, Burhan5
- Pekguc, Ebru5
- Ornek, Serdar5
- Ornek, Serdar5
- 1. Acibadem Altunizade Hosp, Hematol Unit, Istanbul, Turkey
- 2. Acibadem Labcell Cellular Therapy Ctr, Istanbul, Turkey
- 3. Medipol Univ, Hematol Unit, Fac Med, Istanbul, Turkey
- 4. Istanbul Florence Nightingale Hosp, Hematol Unit, Istanbul, Turkey
- 5. VKV Amer Hosp, Hematol Unit, Istanbul, Turkey
Açıklama
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and sustainability. In this preliminary study, the results of the first production and clinical data of an academic CAR-T cell (ISIKOK-19) trial in Turkey are presented.
Dosyalar
10-4274-tjh-galenos-2022-2022-0193.pdf
Dosyalar
(252.3 kB)
| Ad | Boyut | Hepisini indir |
|---|---|---|
|
md5:ad284c6653365d612f4b7c1077502169
|
252.3 kB | Ön İzleme İndir |